Neoplasms

Digestive System Diseases

All Conditions

Rectal Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Rectal Diseases

Patients receive adaptive radiotherapy therapy and concurrent chemotherapy.

A dose of 45Gy will be delivered to planning target volume (PTV)

Online adaptive radiation therapy

In the present study, the investigators will evaluate the efficacy, toxicities, and of online adaptive radiation therapy (ART) for patients with rectal cancer treated with neoadjuvant chemoradiotherapy.

Online Adaptive Radiation Therapy for Rectal Cancer

A Prospective Study to Evaluate Online Adaptive Radiotherapy in Rectal Cancer

evaluated with Common Terminology Criteria for Adverse Events (CTCAE) 5.0

Clinical and pathological complete response and partial response rate after chemoradiotherapy

evaluated with Radiation Therapy Oncology Group (RTOG)/EORTC late radiation morbidity scoring scheme

Planing target volume V100%, defined as the planing target volume receiving at least 100% of the prescribed dose (V100%), is used to evaluate the dose coverage of target volume.

Margins needed in online ART for CTV to planning clinical target volume (PCTV) and GTV to planning gross tumor volume (PGTV) to cover inter/intra-fraction motion

Peking Union Medical College Hospital

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Esophageal Neoplasms

Carcinoma

Prostatic Neoplasms

Head and Neck Neoplasms

Urinary Bladder Neoplasms

Uterine Cervical Neoplasms

Urogenital Neoplasms

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Uterine Neoplasms

Genital Neoplasms, Female

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Esophageal Cancer

Daily cone-beam CT based online adaptive radiation therapy

Goda Kalinauskaite, MD

Carolin Senger, MD

Goda Kalinauskaite

The study focuses on the scientific and clinical evaluation of online adaptive radiotherapy (ART) using the Varian/SHS ETHOS treatment system. In this study, radiation treatment plans are dynamically adjusted on a daily basis over several weeks of therapy to account for anatomical shifts in either the tumour or adjacent normal tissue - a capability that has been difficult to achieve due to technical limitations. With the ETHOS accelerator, such real-time adjustments can be made based on cone beam computed tomography (CBCT). This is a prospective observational study with the primary objective of investigating the feasibility and acceptability of performing ART with ETHOS for different tumour entities. The study will also evaluate the feasibility of integrating multi-parametric data sets into the ART workflow, such as standardised electronic feedback on treatment toxicity from both patients (ePROMS) and physicians (ePRT).

Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)

A Prospective Study on Online Adaptive Radiotherapy (ART) Using the ETHOS Linear Accelerator for Various Tumor Entities and the Feasibility of Integrating Multi-Parametric Patient Data Into the Adaptive Workflow

This measure evaluates the success rate of adaptive radiotherapy sessions with ETHOS across different tumor types. It measures the total count of adaptive treatment sessions that were completed without interruption or complication for each patient.

This measure quantifies the adaptive treatment sessions for which a dosimetric advantage for target coverage is detected in patients undergoing adaptive radiotherapy across different tumor types.

This measure quantifies the adaptive treatment sessions for which a dosimetric advantage for organs at risk is detected in patients undergoing adaptive radiotherapy across different tumor types.

This measure quantifies the adaptive treatment sessions for which in silico analysis identifies a potential dosimetric advantage to organs at risk following ePROMs and ePRT-based plan adjustments.

Frequency and severity of treatment-related toxicities in patients as scored using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (NCI-PRO-CTCAE)

Frequency and severity of treatment-related toxicities in patients as scored using the the Common Terminology Criteria for Adverse Events (CTCAE)

This measure evaluates the quality of life of patients undergoing adaptive radiotherapy using the EORTC QLQ-C30 scale.

This measure quantifies the fatigue experienced by patients undergoing adaptive radiotherapy as determined by the FACIT-F scale.

Freedom from local progression after adaptive radiotherapy

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Online Adaptive Radiation Therapy for Rectal Cancer	NCT05911789	Rectal Cancer	Online adaptive...	18 Years -	Peking Union Medical College Hospital
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)	NCT06116019	Prostate Cancer Head and Neck C... NSCLC SCLC Esophageal Canc... Bladder Cancer Rectum Cancer Cervix Cancer Other Carcinoma	Online adaptive...	18 Years -	Charite University, Berlin, Germany
Online Adaptive Radiation Therapy for Rectal Cancer	NCT05911789	Rectal Cancer	Online adaptive...	18 Years -	Peking Union Medical College Hospital

Spots Global Cancer Trial Database for online adaptive radiation therapy